NLRP3

NLRP3 stands for NOD-like receptor family pyrin domain containing 3. It is a cytosolic protein that plays a central role in the innate immune system by forming the NLRP3 inflammasome.
Key Points

The NLRP3 inflammasome is a multiprotein complex that detects a wide range of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs).
Upon activation, NLRP3 recruits the adaptor protein ASC and pro-caspase-1, leading to the activation of caspase-1.
Activated caspase-1 processes pro-inflammatory cytokines, particularly interleukin-1β (IL-1β) and interleukin-18 (IL-18), into their active forms.
This process results in inflammation and, in some cases, a form of cell death called pyroptosis.

Clinical Relevance

Dysregulation or mutations in NLRP3 are associated with autoinflammatory diseases such as Cryopyrin-Associated Periodic Syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease.
NLRP3 is also implicated in common diseases with inflammatory components, such as gout, type 2 diabetes, atherosclerosis, and Alzheimer’s disease.

Mechanism

NLRP3 activation typically requires two signals:

Priming (e.g., via NF-κB activation by microbial products or cytokines)
Activation (e.g., by ATP, crystalline substances, or cellular stress)

This two-step process ensures tight regulation of inflammasome activation to prevent inappropriate inflammation.

– OpenMD AI Overview

Aluminum / Blood brain barrier / Bradford Hill criteria / Epidemiology / HLA / IL-1β / Lymphocytes / MTHFR / Neuroinflammation / NLRP3 / Toxicants

Aluminum Adjuvants, Autoimmunity, and Autism Spectrum Disorder: AComprehensive Mechanistic, Neuropathological, and Legal Analysis

Conclusions: Converging mechanistic, neuropathological, epidemiological, and genetic
evidence demonstrates that aluminum adjuvants can trigger ASD in genetically susceptible
individuals through well-characterized neuroinflammatory pathways. The 80-fold increase
in ASD prevalence temporally correlating with vaccine schedule expansion, combined with
robust biological mechanisms and postmortem findings, demands urgent re-examination of aluminum adjuvant safety in the context of neurodevelopment, particularly in genetically vulnerable populations.

More
  • February 2, 2026

Archives

Email:
Admin at How Do Vaccines Cause Autism dot org

How Do Vaccines Cause Autism